Frail pts with SLE is associated with 🔸prolonged hospitalizations (28.89%), 🔸significantly higher in-pt mortality (2.88%) 🔸fewer days-to-readmission (59.8%) vs. non-frail pts with SLE (CLeung et al) Screen your SLE pts for frailty too. #ACR23 ABST2590 @RheumNow https://t.co/c4YP5h2ypn

#ACR23 Abstr#2587 Can we agree on how to measure frailty in #SLE? A cohort study: moderate agreement at best among SLICC-FI, SPPB, FRAIL=>2 & PROMIS PF=<40. SLICC-FI was robust predictor of all outcomes except for cognitive impairment. FRAIL & PROMIS not far behind @RheumNow https://t.co/qWjM4crPvg

The Heart of Lupus During ACR 2023 Convergence, several abstracts were presented evaluating the prevalence of CV disease and exploring new tools to predict CV disease. The ones that caught my eye included... https://t.co/5Qk2fF3nlA #ACR23 https://t.co/Rja7K44BUf

• The Heart of Lupus | RheumNow

COVAD2 data: ⬆️proportion of SLE pts from lmHDI countries were on CS(73% vs 59% p=0.0002), antimalarials(81% vs 68% p=0.0002) & IS(66% vs 53%p=0.0009) vs pts from hvhHDI countries Comorbids more in younger pts from lmHDI (prob from CS use) #ACR23 ABST2269 @RheumNow @rheumarhyme https://t.co/4CLGFYG1d0

L17 #ACR23 @RheumNow Afimetoran TLR7/8 inhib for cutaneous lupus Safety: No SAEs, mild-mod AEs, lower than PBO Nasopharyngitis & bronchitis Trough concentration consistent from D8 to 113, support 30 mg qd CLASI change; MCDI 50% Afim v 0% PB, CLASI-50 Afim 50% v 0% Inhib of IFNGS https://t.co/cKYY6rmIWE

L17 @ #ACR23 New therapy on horizon for cutaneous LE (CLE)? ⭐️AFIMETORAN ➡️ TLR7/8 inhibitor ➡️1st-in-class orally bioavailable, potent ⭐️Phase Ib trial ➡️Criteria: 👉18-65 yo SLE vs biopsy proven CLE 👉CLE Dz Area & Severity Index (CLASI-A) at least 6 👉ANA… https://t.co/HPqw4d0AHl https://t.co/5u9aEvzdMb

Telitacicept (BlyS/APRIL inhibitor) ph3 in RA wholly in China, after SLE approval there (SLE trial now w global sites) Efficacy okay, no better than other b/tsDMARDs What's the hook here, in a crowded RA market incl biosimilars? Safety does look good though #ACR23 L20 @RheumNow https://t.co/UzQ0f18E2A

ICYMI Interesting study by Dr LWGarcia et al: 👉IFN-a serum levels predicted failure to respond to tx 2 years after a flare in pts w/ LN 👉Pts w/⬆️BL IFN-a levels had greater risk of having 2 or more subsequent flares #ACR23 ABST2297 @RheumNow @ZahiTouma https://t.co/WJZnNUPUbT

Q for Rheumatologists: How often do you counsel appropriate SLE patients about cervical ca screening and/or vaccination? Re: PAPILUP Study A#1479 #ACR23 - shows PAP findings of HR-HPV+abnml cytology comparable to HIV+ pts @RheumNow